Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1

Interventions

Specimen Handling 80Fluorouracil 74Oxaliplatin 69Magnetic Resonance Spectroscopy 61Leucovorin 58Gemcitabine 55Bevacizumab 55Biopsy 41Capecitabine 40Irinotecan 37Cisplatin 36Nivolumab 35pembrolizumab 33Cetuximab 33durvalumab 30Paclitaxel 27130-nm albumin-bound paclitaxel 27atezolizumab 20Folfox protocol 20Radiotherapy 17Carboplatin 17dehydroftorafur 15Taxes 15Cyclophosphamide 15fludarabine 13X-Rays 13Radiation 13trastuzumab deruxtecan 12Surgical Procedures, Operative 12Albumin-Bound Paclitaxel 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sotigalimab × Gastrointestinal × 30 days × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04130854 2026-05-06

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
58 enrolled
Gastrointestinal

Locally Advanced Rectal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡